• 论著 • 上一篇    下一篇

肝细胞再生磷酸酶-3 、CD105在喉鳞状细胞癌中的表达及意义

胡海丽1,董雪蕾1,2,田秀芬2,3   

  1. 1. 郑州大学第三附属医院
    2.
    3. 郑州大学第一附属医院
  • 收稿日期:2010-10-11 修回日期:2011-01-20 出版日期:2011-06-15 发布日期:2011-06-15
  • 通讯作者: 胡海丽

The expression and significance of PRL-3 and CD105 in laryngeal Squamous Cell Careinoma

  • Received:2010-10-11 Revised:2011-01-20 Published:2011-06-15 Online:2011-06-15

摘要: 【摘要】目的:研究肝细胞再生磷酸酶-3(PRL-3 )、标记血管密度(MVD)的CD105在喉鳞状细胞癌中的表达及意义。方法:采用免疫组化SABC法对69例喉鳞状细胞癌手术切除标本进行PRL-3和MVD检测,并取25例相应癌旁组织作对照。结果:喉鳞状细胞癌PRL-3、CD105表达均与淋巴结转移及临床分期相关(p<0.05);喉鳞状细胞癌中PRL-3与CD105标记的MVD的表达呈显著正相关(p<0.05);喉鳞状细胞癌PRL-3的表达与组织分化程度相关,而MVD(微血管密度)的表达则与组织分化程度无关;结论: PRL-3可能作为一种新的肿瘤标志物,参与了喉鳞状细胞癌血管的生成,对喉鳞状细胞癌转移有促进作用,为下一步研究提供新线索;MVD与喉鳞状细胞癌的转移及临床分期相关,可为喉鳞状细胞癌患者的一个独立的预后指标,并为抗血管治疗提供依据。

关键词: 喉鳞状细胞癌, 肝细胞再生磷酸酶-3, CD105, 微血管密度(MVD)

Abstract: 【Abstract】 Objective Study the expression and the Significance of PRL-3 and Microvessel dencity which was marked with CD l05 in laryngeal Squamous Cell quamous Cell carcinoma and 25 normal tissues was investigated by carcinoma. Methods :Expression of PRL-3 and MVD in samples of 69 laryngeal Susingmmunohistoehemieal methods of SABC respectively. Results:The expression of PhosPhatas of regenerating liver-3( PRL-3 )and MVD has close correlation with clinic stage of laryngeal carcinoma and lymph-node metastasis in carcinoma (p<0.05). PRL-3 hasSignificant correlation with the degree of histological differentiation but Microvessel dencity has no correlation with the degree of histological differentiation; Significant correlation could be established among the expression of microvessel density and PRL-3 (P<0?05).Conclusions:PRL-3 may be involved in laryngeal squamous cell carcinoma angiogenesis and promoted laryngeal squamous cell carcinoma metastasis.MVD had a close correlation with clinic stage of laryngeal carcinoma and lymph-nodemetastasis, It may be a valuable index to evaluate the prognosis of patients with laryngeal squamous cell carcinoma,also, MVD can provide the basis for anti-vascular therapy

Key words: laryngeal Squamous carcinoma, PRL-3, CD105, MVD